Clinical Impact of Positive Surgical Margins in Gastric Adenocarcinoma in the Era of Preoperative Therapy.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
21
12
2022
accepted:
27
03
2023
medline:
7
7
2023
pubmed:
28
4
2023
entrez:
27
4
2023
Statut:
ppublish
Résumé
Microscopically positive (R1) surgical margins after gastrectomy increase gastric cancer recurrence risk, but optimal management after R1 gastrectomy is controversial. We sought to identify the impact of R1 margins on recurrence patterns and survival in the era of preoperative therapy for gastric cancer. Patients who underwent gastrectomy for adenocarcinoma during 1998-2017 at a major cancer center were enrolled. Clinicopathologic factors associated with positive margins were examined, and incidence, sites, and timing of recurrence and survival outcomes were compared between patients with positive and negative margins. Of 688 patients, 432 (63%) received preoperative therapy. Thirty-four patients (5%) had R1 margins. Compared with patients with negative margins, patients with R1 margins more frequently had aggressive clinicopathologic features, such as linitis plastica (odds ratio [OR] 7.79, p < 0.001) and failure to achieve cT downstaging with preoperative treatment (OR 5.20, p = 0.005). The 5 year overall survival (OS) rate was lower in patients with R1 margins (6% vs 60%; p < 0.001), and R1 margins independently predicted worse OS (hazard ratio 2.37, 95% CI 1.51-3.75, p < 0.001). Most patients with R1 margins (58%) experienced peritoneal recurrence, and locoregional recurrence was relatively rare in this group (14%). Median time to recurrence was 8.5 months for peritoneal dissemination and 15.7 months for locoregional recurrence. R1 margins after gastrectomy were associated with aggressive tumor biology, high incidence of peritoneal recurrence after a short interval, and poor OS. In patients with R1 margins, re-resection to achieve microscopically negative margins has to be considered with caution.
Sections du résumé
BACKGROUND
BACKGROUND
Microscopically positive (R1) surgical margins after gastrectomy increase gastric cancer recurrence risk, but optimal management after R1 gastrectomy is controversial. We sought to identify the impact of R1 margins on recurrence patterns and survival in the era of preoperative therapy for gastric cancer.
METHODS
METHODS
Patients who underwent gastrectomy for adenocarcinoma during 1998-2017 at a major cancer center were enrolled. Clinicopathologic factors associated with positive margins were examined, and incidence, sites, and timing of recurrence and survival outcomes were compared between patients with positive and negative margins.
RESULTS
RESULTS
Of 688 patients, 432 (63%) received preoperative therapy. Thirty-four patients (5%) had R1 margins. Compared with patients with negative margins, patients with R1 margins more frequently had aggressive clinicopathologic features, such as linitis plastica (odds ratio [OR] 7.79, p < 0.001) and failure to achieve cT downstaging with preoperative treatment (OR 5.20, p = 0.005). The 5 year overall survival (OS) rate was lower in patients with R1 margins (6% vs 60%; p < 0.001), and R1 margins independently predicted worse OS (hazard ratio 2.37, 95% CI 1.51-3.75, p < 0.001). Most patients with R1 margins (58%) experienced peritoneal recurrence, and locoregional recurrence was relatively rare in this group (14%). Median time to recurrence was 8.5 months for peritoneal dissemination and 15.7 months for locoregional recurrence.
CONCLUSION
CONCLUSIONS
R1 margins after gastrectomy were associated with aggressive tumor biology, high incidence of peritoneal recurrence after a short interval, and poor OS. In patients with R1 margins, re-resection to achieve microscopically negative margins has to be considered with caution.
Identifiants
pubmed: 37106276
doi: 10.1245/s10434-023-13495-3
pii: 10.1245/s10434-023-13495-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4936-4945Subventions
Organisme : NIH/NCI
ID : P30CA016672
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Kang YK, Yook JH, Park YK, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39(26):2903–13.
doi: 10.1200/JCO.20.02914
pubmed: 34133211
pmcid: 8425847
Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. The Lancet Oncol. 2021;22(8):1081–92.
doi: 10.1016/S1470-2045(21)00297-7
pubmed: 34252374
Ajani JA, D’Amico TA, Bentrem DJ, et al. Gastric cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2022;20(2):167–92.
doi: 10.6004/jnccn.2022.0008
Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1–21.
doi: 10.1007/s10120-020-01042-y
Wang S-Y, Yeh C-N, Lee H-L, et al. Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol. 2009;16(10):2738–43.
doi: 10.1245/s10434-009-0616-0
pubmed: 19636636
Nagata T, Ichikawa D, Komatsu S, et al. Prognostic impact of microscopic positive margin in gastric cancer patients. J Surg Oncol. 2011;104(6):592–7.
doi: 10.1002/jso.22022
pubmed: 21744353
Bickenbach KA, Gonen M, Strong V, Brennan MF, Coit DG. Association of positive transection margins with gastric cancer survival and local recurrence. Ann Surg Oncol. 2013;20(8):2663–8.
doi: 10.1245/s10434-013-2950-5
pubmed: 23536054
Kumazu Y, Hayashi T, Yoshikawa T, et al. Risk factors analysis and stratification for microscopically positive resection margin in gastric cancer patients. BMC Surg. 2020;20(1):95.
doi: 10.1186/s12893-020-00744-5
pubmed: 32380979
pmcid: 7204060
Zhao B, Lu H, Bao S, et al. Impact of proximal resection margin involvement on survival outcome in patients with proximal gastric cancer. J Clin Pathol. 2020;73(8):470–5.
doi: 10.1136/jclinpath-2019-206305
pubmed: 31879270
Fujita S, Oshima Y, Yajima S, et al. What are the important prognostic factors in gastric cancer with positive duodenal margins? A multi-institutional analysis. Surg Today. 2021;51(4):561–7.
doi: 10.1007/s00595-020-02110-7
pubmed: 32797287
Nakanishi K, Kanda M, Ito S, et al. Prognostic impact of a microscopic positive margin in patients undergoing gastrectomy for gastric cancer: a propensity score-matched analysis of a multi-institutional dataset. Surg Today. 2022;52(4):559–66.
doi: 10.1007/s00595-021-02365-8
pubmed: 34436686
Tu RH, Lin JX, Wang W, et al. Pathological features and survival analysis of gastric cancer patients with positive surgical margins: a large multicenter cohort study. Eur J Surg Oncol. 2019;45(12):2457–64.
doi: 10.1016/j.ejso.2019.06.026
pubmed: 31362841
Bissolati M, Desio M, Rosa F, et al. Risk factor analysis for involvement of resection margins in gastric and esophagogastric junction cancer: an Italian multicenter study. Gastric Cancer. 2017;20(1):70–82.
doi: 10.1007/s10120-015-0589-6
pubmed: 26732876
Shen JG, Cheong JH, Hyung WJ, Kim J, Choi SH, Noh SH. Influence of a microscopic positive proximal margin in the treatment of gastric adenocarcinoma of the cardia. World J Gastroenterol. 2006;12(24):3883–6.
doi: 10.3748/wjg.v12.i24.3883
pubmed: 16804975
pmcid: 4087938
Postlewait LM, Maithel SK. The importance of surgical margins in gastric cancer. J Surg Oncol. 2016;113(3):277–82.
doi: 10.1002/jso.24110
pubmed: 26662226
Mine S, Kurokawa Y, Takeuchi H, et al. Postoperative complications after a transthoracic esophagectomy or a transhiatal gastrectomy in patients with esophagogastric junctional cancers: a prospective nationwide multicenter study. Gastric Cancer. 2022;25(2):430–7.
doi: 10.1007/s10120-021-01255-9
pubmed: 34590178
Makuuchi R, Irino T, Tanizawa Y, Bando E, Kawamura T, Terashima M. Pancreaticoduodenectomy for gastric cancer. J Cancer Metastasis Treat. 2018;4(6):26.
doi: 10.20517/2394-4722.2018.15
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.
doi: 10.1056/NEJMoa010187
pubmed: 11547741
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
doi: 10.1056/NEJMoa055531
pubmed: 16822992
Ikoma N, Das P, Hofstetter W, et al. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006–2014 using propensity score matching. Gastric Cancer. 2018;21(6):1004–13.
doi: 10.1007/s10120-018-0832-z
pubmed: 29730720
pmcid: 6515902
Ikoma N, Agnes A, Chen HC, et al. Linitis plastica: a distinct type of gastric cancer. J Gastrointest Surg. 2020;24(5):1018–25.
doi: 10.1007/s11605-019-04422-7
pubmed: 31754987
Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.
doi: 10.3322/caac.21388
pubmed: 28094848
Burgart LJ, Chopp WV, Jain D. Protocol for the examination of specimens from patients with carcinoma of the stomach Version: 4.2.1.0. College of American Pathologists; 2021.
Badgwell B, Blum M, Estrella J, et al. Predictors of survival in patients with resectable gastric cancer treated with preoperative chemoradiation therapy and gastrectomy. J Am Coll Surg. 2015;221(1):83–90.
doi: 10.1016/j.jamcollsurg.2015.04.004
pubmed: 26002780
Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22(14):2774–80.
doi: 10.1200/JCO.2004.01.015
pubmed: 15254045
Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24(24):3953–8.
doi: 10.1200/JCO.2006.06.4840
pubmed: 16921048
Aurello P, Magistri P, Nigri G, et al. Surgical management of microscopic positive resection margin after gastrectomy for gastric cancer: a systematic review of gastric R1 management. Anticancer Res. 2014;34(11):6283–8.
pubmed: 25368226
Squires MH 3rd, Kooby DA, Pawlik TM, et al. Utility of the proximal margin frozen section for resection of gastric adenocarcinoma: a 7-Institution Study of the US Gastric Cancer Collaborative. Ann Surg Oncol. 2014;21(13):4202–10.
doi: 10.1245/s10434-014-3834-z
pubmed: 25047464
Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017;3:17036.
doi: 10.1038/nrdp.2017.36
pubmed: 28569272
Muneoka Y, Ohashi M, Ishizuka N, et al. Risk factors and oncological impact of positive resection margins in gastrectomy for cancer: are they salvaged by an additional resection? Gastric Cancer. 2022;25(1):287–96.
doi: 10.1007/s10120-021-01238-w
pubmed: 34420098
Li C, Oh SJ, Kim S, et al. Macroscopic Borrmann type as a simple prognostic indicator in patients with advanced gastric cancer. Oncology. 2009;77(3–4):197–204.
doi: 10.1159/000236018
pubmed: 19729977
Jung K, Park MI, Kim SE, Park SJ. Borrmann type 4 advanced gastric cancer: focus on the development of scirrhous gastric cancer. Clin Endosc. 2016;49(4):336–45.
doi: 10.5946/ce.2016.057
pubmed: 27456608
pmcid: 4977748
Song XH, Zhang WH, Kai L, et al. Prognostic impact of Borrmann classification on advanced gastric cancer: a retrospective cohort from a single institution in western China. World J Surg Oncol. 2020;18(1):204.
doi: 10.1186/s12957-020-01987-5
pubmed: 32792016
pmcid: 7427284
Cho BC, Jeung HC, Choi HJ, et al. Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute. J Surg Oncol. 2007;95(6):461–8.
doi: 10.1002/jso.20731
pubmed: 17192913
Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005.
doi: 10.1016/j.annonc.2022.07.004
pubmed: 35914639
Aurello P, Sirimarco D, Magistri P, et al. Management of duodenal stump fistula after gastrectomy for gastric cancer: systematic review. World J Gastroenterol. 2015;21(24):7571–6.
doi: 10.3748/wjg.v21.i24.7571
pubmed: 26140005
pmcid: 4481454